Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ranibizumab for Age-Related Macular Degeneration and the Risk of Arterial Thromboembolic Events (RATE)

NCT01319188 is registered in ClinicalTrials.gov with Ural State Medical University as lead sponsor.

NCT NCT01319188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01319188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ranibizumab for Age-Related Macular Degeneration and the Risk of Arterial Thromboembolic Events (RATE)
Lead sponsor
Ural State Medical University
Phase
Phase 4
Overall status
Terminated
Start date
June 30, 2010
Completion date
April 30, 2015
Enrollment
380 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, cerebrovascular disorders, coronary artery disease